F
Fabien Zoulim
Researcher at French Institute of Health and Medical Research
Publications - 716
Citations - 40988
Fabien Zoulim is an academic researcher from French Institute of Health and Medical Research. The author has contributed to research in topics: Hepatitis B virus & Hepatitis B. The author has an hindex of 96, co-authored 641 publications receiving 35807 citations. Previous affiliations of Fabien Zoulim include Hotel Dieu Hospital & University of Orléans.
Papers
More filters
Journal ArticleDOI
Molecular genetics of HBV infection.
Stephen Locarnini,Fabien Zoulim +1 more
TL;DR: The role of host genetics in influencing the outcome of HBV disease in the context of natural history and therapy is beginning to aid understanding in pathogenesis and, when this knowledge is linked to pathogen-specific databases, this should translate into more individualized patient care.
Journal ArticleDOI
Monitoring drug resistance in chronic hepatitis B virus (HBV)-infected patients during lamivudine therapy: evaluation of performance of INNO-LiPA HBV DR assay.
Anna S. F. Lok,Fabien Zoulim,Stephen Locarnini,Alessandra Mangia,Grazia Anna Niro,Hilde Decraemer,Geert Maertens,Frank Hulstaert,Karen De Vreese,Erwin Sablon +9 more
TL;DR: Results demonstrate that INNO-LiPA HBV DR is a highly sensitive and easily applicable assay for the detection and monitoring of lamivudine-resistant mutations in chronic hepatitis B patients and that the assay is more sensitive than sequencing in detecting mixed mutant and wild-type sequences.
Journal ArticleDOI
Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response
Roeland Zoutendijk,Jurriën G.P. Reijnders,Ashley Brown,Fabien Zoulim,David Mutimer,Katja Deterding,Jörg Petersen,Wolf Peter Hofmann,Maria Buti,Teresa Santantonio,Florian van Bömmel,Pierre Pradat,Y.H. Oo,M. Luetgehetmann,Thomas Berg,Bettina E. Hansen,Heiner Wedemeyer,Harry L.A. Janssen +17 more
TL;DR: ETV monotherapy can be continued in NA‐naïve patients with detectable HBV DNA at week 48, particularly in those with a low viral load because long‐term ETV leads to a virological response in the vast majority of patients.
Journal ArticleDOI
Long term histological improvement and clearance of intrahepatic hepatitis C virus RNA following sustained response to interferon-ribavirin combination therapy in liver transplanted patients with hepatitis C virus recurrence
T Bizollon,Si Nafa Si Ahmed,S. Radenne,M. Chevallier,Philippe Chevallier,Parviz Parvaz,S. S. Guichard,Christian Ducerf,Jacques Baulieux,Fabien Zoulim,C. Trepo +10 more
TL;DR: In patients with biochemical and virological responses induced by ribavirin and interferon, a complete response was sustained in 93% for at least three years after cessation of therapy, associated with absence of detectable intrahepatic hepatitis C RNA and marked histological improvement.
Journal ArticleDOI
Stepwise process for the development of entecavir resistance in a chronic hepatitis B virus infected patient.
Stéphanie Villet,A. Ollivet,Christian Pichoud,Luc Barraud,Jean-Pierre Villeneuve,Christian Trepo,Fabien Zoulim +6 more
TL;DR: Genotypic and phenotypic analysis provided additional information to understand the process of HBV variant selection, and reported the selection of complex HBV mutants that escaped lamivudine and entecavir antiviral pressures.